To establish whether neuroblastoma sensitivity to IBL‐302 was due to triple target inhibition or whether the effects were conferred by PI3K pathway inhibition, GI50 values were compared between IBL‐302 and the PI3K/mTOR inhibitors dactolisib, PI‐103, and omipalisib, the mTOR inhibitor AZD8055, and the ribosomal S6 kinase (RSK)/PIM inhibitor SL0101 using GDSC data. The gene discussed is PIM1; the disease is neuroblastoma.